Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

dewmoore Aug. 4 at 9:09 PM

$SLS Family Tree check... 👀 Tom Cavanaugh was just named EVP & Worldwide Chairman of Innovative Medicine at $JNJ Guess who sits on the Board of Directors at $SLS ??? Katherine Bach Kalin. Guess where they both spent years overlapping as high-level executives in global strategy and product development from 2012 to 2017? CELGENE Celgene: BOTH Tom and Katherine overlapped as senior executives in global strategy/product development (2012–2017). $JNJ : Katherine spent nearly a decade at J&J in leadership/business development (2002–2011). You really think these two haven't grabbed a coffee or drinks in the past few days to catch up? 😂☕️🍻 Connect the dots! https://ca.finance.yahoo.com/news/johnson-johnson-executive-vice-president-124500987.html

0 · Reply

Gebinator Aug. 4 at 8:53 PM

$SLS And -- is $JNJ promoting key staff for good strategic reasons? https://ca.finance.yahoo.com/news/johnson-johnson-executive-vice-president-124500987.html

0 · Reply

dewmoore Aug. 4 at 8:52 PM

$SLS Great to see a $JNJ Product Director showing respect to Dr. Stergiou and $SLS, but let’s not read too much into it. Product Directors manage brand lifecycles, not secret corporate buyouts under strict NDAs. It’s great validation, but if J&J actually had an active NDA in play, corporate legal wouldn't let anyone give public high-fives on social media or anywhere else including LinkedIn It’s fun to dream, but stay grounded for now.... from me to you I still say my top 3 buyout boys are : #1 $MRK #2 $JNJ #3 $LLY

2 · Reply

SellasgpsCurativeBAT11 Aug. 4 at 8:19 PM

$SLS $JNJ🤐 Den yparchei típota na deite edó. 👇 ✌️🙏❤️‍🩹

0 · Reply

RarelyRight Aug. 4 at 7:54 PM

$DFTX $JNJ $CMPS $ATAI JNJ has to buy one of these. Spravato is going to get destroyed by psychedelics.

1 · Reply

Johnmtnb2018 Aug. 4 at 7:47 PM

$SLS $JNJ Looks like JNJ is the winner !

2 · Reply

Mountainmannn Aug. 4 at 7:41 PM

$ABUS I'd love to see $JNJ come in here buy us for 11 billion in stock...

1 · Reply

OmarKingW Aug. 4 at 6:43 PM

$IBRX $JNJ $MRK VERY BULLISH FOR LONG INVESTORS: Things still moving ahead cleanly. Growth continues with more than 50m revenue and the only thing that hurt the numbers is 230.4m (.22 per share) spending vs 92.6m (.09 per share)from prior year) NON Cash accounting charges. Street expected the loss to be .08-.09 per share. The explanation is very clear from the company to me n it’s a cost of rapid growth for the year activating convertible notes, warrants, and related derivative liabilities. The widening seems concerning but it’s not in reality because we did grow rapidly from $1.80 all the way to $12. THE STORY BEEING TOLD IS NOTHING CHANGES GROWTH AND EXPANSION CONTINUES RESULTING INTO SOME OF THE NON CASH SPIKE) THESE WILL BE MANGED GOING FORWARD AND WILL REDUSE SIGNIFICANTLY GOING FORWARD. THINK: LONG AND STRONG 💪🏼

0 · Reply

Diefreeandsell Aug. 4 at 6:19 PM

$IBRX $JNJ $MRK VOLUME wow it's really great today. No catastrophe! 14.15mil shares, +14% compared to typical volume of 12.41mil by 2:09 pm ET. Typical daily volume is 19.4mil shares over the past 6 months. Co's commercial execution has significantly altered its financial risk profile over the past few quarters. It just reported its Q2 2026 financials, delivering $50.7 million in net product revenue from ANKTIVA in USA only. This is up 92% year-over-year and marks the eighth consecutive quarter of sequential revenue growth since launch, you're disappointed? WTF Bottom Line: The current $357M+ cash pile, paired with an ANKTIVA commercial run rate now exceeding $200 million annually, provides ImmunityBio with a stable runway through late 2027. Late 2027-WTF!!! This comfortably covers the company past its crucial January 6, 2027 PDUFA date and right up to the anticipated late-2026 BCG-naïve FDA submission window. You think it won't succeed, think again!

1 · Reply

H_hi Aug. 4 at 5:31 PM

$NVO we need to merge with $JNJ asap!

0 · Reply

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

2026-08-04T12:50:51.000Z - 8 hours ago

Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

Aug 4, 2026, 8:45 AM EDT - 8 hours ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 3, 2026, 8:00 AM EDT - 1 day ago

Johnson & Johnson Transcript: Investor update

2026-08-03T11:00:29.000Z - 1 day ago

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

2026-08-03T09:35:43.000Z - 1 day ago

Johnson & Johnson removed from US Conviction List at Goldman Sachs

Aug 2, 2026, 8:00 AM EDT - 2 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

2026-07-30T12:35:46.000Z - 5 days ago

Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review

Jul 30, 2026, 8:30 AM EDT - 5 days ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 29, 2026, 6:13 PM EDT - 5 days ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 5:42 PM EDT - 5 days ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

2026-07-29T21:40:31.000Z - 5 days ago

Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36

Jul 29, 2026, 5:38 PM EDT - 5 days ago

Johnson & Johnson lowers 2026 profit forecast

2026-07-29T21:35:31.000Z - 5 days ago

Johnson & Johnson cuts FY26 EPS view to $10.86-$11.01, consensus $11.68

2026-07-29T21:35:19.000Z - 5 days ago

Johnson & Johnson affirms FY26 revenue view of $100.8B-$101.4B

Jul 29, 2026, 5:28 PM EDT - 5 days ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 12:01 PM EDT - 6 days ago

Explainer: Can J&J finally put the talc litigation behind it?

2026-07-29T13:31:13.000Z - 6 days ago

Johnson & Johnson price target raised to $300 from $290 at Argus

Jul 28, 2026, 4:31 PM EDT - 7 days ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 12:26 PM EDT - 7 days ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

2026-07-28T06:59:19.000Z - 7 days ago

J&J Strikes $5.5B Talc Settlement after Years of Lawsuits; JNJ Stock Rises

Jul 28, 2026, 1:03 AM EDT - 7 days ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 12:31 AM EDT - 7 days ago

J&J offers $5.5bn to settle baby powder lawsuits

Jul 27, 2026, 9:29 PM EDT - 7 days ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 6:47 PM EDT - 7 days ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:31 PM EDT - 7 days ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 5:45 AM EDT - 8 days ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

2026-07-23T12:35:56.000Z - 12 days ago

Johnson & Johnson’s multiple myeloma therapy shows efficacy in Phase 3 trial

$TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma$

Jul 23, 2026, 8:30 AM EDT - 12 days ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 22, 2026, 4:33 PM EDT - 13 days ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

2026-07-22T14:32:43.000Z - 13 days ago

Johnson & Johnson Continues Recovery After Green Light Given to ‘Next Era’ Robotic Surgeon

ISRG MDT

2026-07-22T14:24:28.000Z - 13 days ago

Johnson & Johnson Stock (JNJ) Rises as Robotic Surgery Device Is Approved

ISRG MDT

Jul 22, 2026, 7:21 AM EDT - 13 days ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:00 AM EDT - 13 days ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 21, 2026, 6:30 PM EDT - 13 days ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Jul 16, 2026, 8:11 AM EDT - 19 days ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:00 AM EDT - 19 days ago

DePuy Synthes Acquires Expanding Innovations™

Jul 15, 2026, 12:09 PM EDT - 20 days ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 7:27 AM EDT - 20 days ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Jul 15, 2026, 6:35 AM EDT - 20 days ago

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:33 AM EDT - 20 days ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:25 AM EDT - 20 days ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:23 AM EDT - 20 days ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:20 AM EDT - 20 days ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 9, 2026, 1:00 PM EDT - 26 days ago

The Big 3: UNH, KO, JNJ

KO UNH

Jul 8, 2026, 7:45 AM EDT - 27 days ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 6, 2026, 6:29 PM EDT - 4 weeks ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Jun 26, 2026, 2:39 PM EDT - 5 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Jun 26, 2026, 12:35 PM EDT - 5 weeks ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 25, 2026, 5:00 AM EDT - 5 weeks ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 15, 2026, 6:00 AM EDT - 7 weeks ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 7 weeks ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 7 weeks ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 11, 2026, 7:45 AM EDT - 7 weeks ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:14 AM EDT - 7 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

Jun 11, 2026, 2:03 AM EDT - 7 weeks ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 7 weeks ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 7 weeks ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 2 months ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 2 months ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 8:08 AM EDT - 2 months ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 5, 2026, 6:24 PM EDT - 2 months ago

J&J beats lawsuit alleging that talc caused three women's cancer

dewmoore Aug. 4 at 9:09 PM

0 · Reply

Gebinator Aug. 4 at 8:53 PM

$SLS And -- is $JNJ promoting key staff for good strategic reasons? https://ca.finance.yahoo.com/news/johnson-johnson-executive-vice-president-124500987.html

0 · Reply

dewmoore Aug. 4 at 8:52 PM

2 · Reply

SellasgpsCurativeBAT11 Aug. 4 at 8:19 PM

$SLS $JNJ🤐 Den yparchei típota na deite edó. 👇 ✌️🙏❤️‍🩹

0 · Reply

RarelyRight Aug. 4 at 7:54 PM

$DFTX $JNJ $CMPS $ATAI JNJ has to buy one of these. Spravato is going to get destroyed by psychedelics.

1 · Reply

Johnmtnb2018 Aug. 4 at 7:47 PM

$SLS $JNJ Looks like JNJ is the winner !

2 · Reply

Mountainmannn Aug. 4 at 7:41 PM

$ABUS I'd love to see $JNJ come in here buy us for 11 billion in stock...

1 · Reply

OmarKingW Aug. 4 at 6:43 PM

0 · Reply

Diefreeandsell Aug. 4 at 6:19 PM

1 · Reply

H_hi Aug. 4 at 5:31 PM

$NVO we need to merge with $JNJ asap!

0 · Reply

LindaRitter799 Aug. 4 at 5:27 PM

$XLF $PLAY $JNJ $ABTC $NNDM XLF tracks major financial institutions, Dave & Buster's benefits from entertainment demand, Johnson & Johnson provides defensive healthcare exposure, American Battery Technology advances recycling, and Nano Dimension develops additive electronics.

1 · Reply

TheUnmaker Aug. 4 at 5:05 PM

$TNXP Looks bottomed to me. $PFE $JNJ $PG $SLS

2 · Reply

Diefreeandsell Aug. 4 at 4:08 PM

$IBRX Most right but one big diff is that IBRX had better sales than $JNJ Inlexo and prob gained more mkt share to boot . It was lack of BCG from $MRK that kept uSA sales from being even higher. That's about to be remedied later this year and sales should improve dramatically in US and take off in SA and UAE. Oh and wait till BCP naïve indication gets approved!! Need more BCG!!

1 · Reply

CHARTBUSTER12 Aug. 4 at 1:49 PM

$JNJ GOOD morning my friends JNJ one of my picks in 2026 for a move higher above 300 dollars. MY friends this a great run company and i do expect bigger things for JNJ this year . HAVE a blessed day

0 · Reply

focafoca99 Aug. 4 at 1:40 PM

$JNJ just announced EVP Jennifer Taubert will retire from Innovative Medicine effective Sept 1, 2026. https://www.rapidticker.com/news/jnj-sec-filing-8-k-5282b6

0 · Reply

Diefreeandsell Aug. 4 at 1:10 PM

$IBRX you forgot to mention growing sales against competition from major commercial launch from $JNJ inlexo! Co grew market share despite that! Double digit growth for anktiva, 15% qtr over qtr shows gaining traction not eroding due to any competition from bp.

0 · Reply

Diefreeandsell Aug. 4 at 11:54 AM

$IBRX This is actually great since looks like the core revenue stream recorded for Q2 2026 remains almost entirely U.S. . Sales grew and not impacted by competition from $JNJ. The rest of world sales will come next qtr, but USA sales are outstanding!

1 · Reply

BENNYST Aug. 4 at 10:22 AM

$SLS $JNJ $PFE evaluating a buyout, Dr. Stergiou must look beyond the money. Public optics and politics matter. Pfizer ($PFE) currently suffers from a terribly negative public image due to Fauci’s legal battles and his invocation of the Fifth Amendment, directly tied to Pfizer's COVID vaccines. Partnering with them is a brand disaster. Meanwhile, Johnson & Johnson ($JNJ) aligns perfectly with oncology maintenance, enjoys superior public standing, and fits Washington's wavelength (echoing Stergiou's Fox News ties). If a buyout happens, choosing J&J over Pfizer is a masterstroke. Choose J&J. 🚀 Bullish

6 · Reply

Dr_Yolo Aug. 4 at 7:39 AM

$JNJ $SLS

0 · Reply

quezoitm Aug. 4 at 3:59 AM

$SLS What isn’t obvious is what a coup buying $SLS will be for whoever wins the bid. Buying the next evolution in cancer care that could target 20+ cancers, is non toxic, dramatically extends patients lives and quality of life will add 10% to the share price of a large pharmaceutical. If $JNJ pays $30B for $SLS but adds 10% to their $600B market cap they’ll be getting Sellas Life Sciences for free. They’ll get paid to buy the damn company! Print a hazard ratio below 0.5 and it’s gonna be a bidding war. That’s capitalism.

5 · Reply

ElliottwaveForecast Aug. 4 at 1:12 AM

$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ

0 · Reply

NEWBIGTECH Aug. 3 at 5:07 PM

$SLS SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Regal trial. 36.9% institutional ownership of $SLS WILL $JNJ $MRK $BMY start a bidding war?

0 · Reply

Market Cap	617.78B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	23.56
Forward PE	21.88
Profit Margin	28.46%
Debt to Equity Ratio	0.44

Volume	7,097,243
Avg Vol	8,353,986
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	15%
Beta	0.24
Analysts	Strong Sell
Price Target	$273.67